Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Date:8/29/2012

SAN DIEGO, Aug. 29, 2012 /PRNewswire/ --Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, September 5, 2012 at 2:40pm Eastern Time (11:40am Pacific Time) during the Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel in Boston.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investors section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the "Investors" page of www.cadencepharm.com under "Events and Presentations." 



Contacts:

William R. LaRue

SVP, CFO                                     

Cadence Pharmaceuticals, Inc.

858-436-1400




'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
2. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
3. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
4. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
5. Isis Pharmaceuticals to receive $1.4 million from Alnylam
6. Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director
7. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
8. Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
9. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
10. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
11. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... ... 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, joins ... Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, MD, ... Officer at Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May 6 - ... on steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in ... will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
Breaking Medicine News(10 mins):